Amedisys Inc (NASDAQ:AMED) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Jefferies Group LLC restated a “buy” rating and set a $57.00 price objective on shares of Amedisys in a research note on Friday, April 28th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Wednesday, May 3rd. Royal Bank Of Canada restated a “hold” rating and set a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Finally, Stephens raised their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $56.50.

Amedisys (NASDAQ:AMED) opened at 48.56 on Friday. The firm has a market capitalization of $1.64 billion, a PE ratio of 41.50 and a beta of 0.89. Amedisys has a one year low of $34.58 and a one year high of $65.91. The stock has a 50 day moving average of $59.50 and a 200-day moving average of $54.23.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 EPS. On average, equities analysts predict that Amedisys will post $2.21 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Downgrades Amedisys Inc (AMED) to Sell” was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/07/bidaskclub-downgrades-amedisys-inc-amed-to-sell.html.

In related news, Director Bruce D. Perkins bought 500 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were purchased at an average cost of $59.69 per share, with a total value of $29,845.00. Following the completion of the transaction, the director now directly owns 13,331 shares of the company’s stock, valued at $795,727.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Lawrence R. Pernosky sold 11,500 shares of the stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $58.97, for a total value of $678,155.00. Following the completion of the sale, the insider now directly owns 30,093 shares in the company, valued at $1,774,584.21. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock worth $1,954,125 over the last ninety days. 2.80% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Swiss National Bank raised its stake in shares of Amedisys by 1.8% in the first quarter. Swiss National Bank now owns 44,300 shares of the health services provider’s stock valued at $2,263,000 after buying an additional 800 shares in the last quarter. Comerica Bank raised its stake in shares of Amedisys by 4.2% in the first quarter. Comerica Bank now owns 30,909 shares of the health services provider’s stock valued at $1,670,000 after buying an additional 1,258 shares in the last quarter. Suntrust Banks Inc. raised its stake in shares of Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock valued at $279,000 after buying an additional 107 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Amedisys by 125.0% in the first quarter. Bank of New York Mellon Corp now owns 781,256 shares of the health services provider’s stock valued at $39,915,000 after buying an additional 433,956 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock valued at $61,347,000 after buying an additional 717,939 shares in the last quarter. 99.80% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.